FY2025 · ended Dec 31, 2025 · Revenue $11.04B, +11.8% YoY · Filed Feb 26, 2026
Quest Diagnostics Inc (DGX) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $11.0 billion and net income of $992.0 million. Free cash flow was $1.4 billion. As of Sep 30, 2026 it held $797.0 million in cash and investments and $6.3 billion in total debt.
Revenue (TTM)
$11.84B
+9.1% vs year-ago TTM
Net income (TTM)
$1.13B
+16.5% vs year-ago TTM
Operating cash flow (TTM)
$1.95B
+3.5% vs year-ago TTM
Free cash flow (TTM)
$1.38B
-1.3% vs year-ago TTM
EPS (TTM)
$10.06
+18.1% vs year-ago TTM
Dividend per share
$1.80
+9.1% vs prior year
Shares outstanding
109.87M
-1.0% vs prior year
Net cash
$-5.49B
as of Sep 30, 2026
Operating margin
14.6%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- DGX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Secaucus, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1022079
- Former names
- CORNING CLINICAL LABORATORIES INC (until Mar 19, 1997)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $11.0B | $9.9B | $9.3B | $9.9B | $10.8B |
| Operating income | $1.6B | $1.3B | $1.3B | $1.4B | $2.4B |
| Net income | $992.0M | $871.0M | $854.0M | $946.0M | $2.0B |
| Diluted EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Operating cash flow | $1.9B | $1.3B | $1.3B | $1.7B | $2.2B |
| Free cash flow | $1.4B | $909.0M | $864.0M | $1.3B | $1.8B |
| Total assets | $16.2B | $16.2B | $14.0B | $12.8B | $13.6B |
| Stockholders' equity | $7.2B | $6.8B | $6.3B | $5.9B | $6.4B |
| Cash and investments | $420.0M | $549.0M | $688.0M | $317.0M | $873.0M |
| Total debt | $6.4B | $6.9B | $5.4B | $4.6B | $4.7B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 23, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 6, 2026 | Oct 6, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 23, 2026 | Jul 23, 2026 |
All 1001 Quest Diagnostics Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.